The Unani system of medicine, rooted in Greco-Arab traditions, has experienced a notable resurgence in modern healthcare, offering promising approaches for disease management and preventive care. This review explores recent practical advances in Unani medicine, focusing on its epidemiological significance, pathophysiological underpinnings, risk stratification, clinical manifestations, diagnostic processes, and contemporary therapeutic interventions. We examine emerging evidence, guideline recommendations, and the integration of Unani into mainstream medical practice, with attention to scientific rigor and clinical applicability for physicians and healthcare professionals.
Unani medicine represents a time-tested holistic healthcare system with origins tracing back to Hippocrates and Galen, later refined by eminent scholars in the Islamic Golden Age. Its principles emphasize the balance of four humors and the interplay of temperament (Mizaj) in health and disease. With growing interest in integrative and complementary medicine, Unani’s role in modern clinical settings warrants detailed exploration. This article synthesizes current literature and clinical guidelines to elucidate practical advances in Unani medicine, aiming to equip healthcare professionals with evidence-based insights for implementation in patient care.
Unani medicine is increasingly applied in the management of chronic diseases such as diabetes mellitus, gastrointestinal disorders, dermatological conditions, and metabolic syndrome. Epidemiological surveys indicate a significant burden of these conditions in South Asia, the Middle East, and North Africa, where Unani continues to be practiced alongside conventional medicine. Data from the World Health Organization highlight the relevance of complementary systems in addressing the unmet needs of populations with limited access to allopathic care, further emphasizing the need for integrated healthcare models that incorporate Unani approaches. The growing prevalence of lifestyle-related disorders has propelled Unani’s preventive and therapeutic paradigms into the spotlight, particularly in resource-constrained regions.
Unani conceptualizes disease as a result of humoral imbalance, where derangements in Dam (blood), Balgham (phlegm), Safra (yellow bile), and Sauda (black bile) disrupt homeostasis. Recent advances in systems biology and molecular medicine have provided mechanistic insights aligning Unani principles with modern pathophysiology, such as oxidative stress, chronic inflammation, and metabolic dysregulation. For instance, Unani formulations targeting hepatobiliary disorders exhibit antioxidant and anti-inflammatory properties, supporting their use in conditions like hepatitis and non-alcoholic fatty liver disease (NAFLD). These findings underscore the mechanistic plausibility of Unani interventions in modulating disease processes at the cellular and molecular levels.
Risk stratification in Unani is traditionally based on individual temperament, dietary habits, environmental exposures, and lifestyle factors. Modern risk assessment tools now integrate Unani profiling with established clinical predictors. For instance, individuals with a Damvi (sanguine) temperament may exhibit predisposition to hypertension or cardiovascular diseases, while Balghami (phlegmatic) individuals are more prone to obesity and metabolic syndrome. Environmental factors such as climate and seasonal changes are also considered influential, and recent studies have validated these associations using epidemiological and biomarker analyses, enhancing the precision of risk identification and preventive strategies.
Unani practitioners emphasize a nuanced assessment of symptoms, integrating both subjective complaints and objective findings. Clinical evaluation involves detailed history-taking, pulse diagnosis (Nabz), examination of tongue, urine, and stool, as well as assessment of physical constitution. Common clinical features addressed by Unani include digestive disturbances, musculoskeletal pain, cutaneous lesions, and fatigue. Recent clinical audits demonstrate that Unani-based symptom clusters closely correlate with conventional disease entities, supporting its diagnostic validity. The holistic approach ensures that comorbidities and psychosocial factors are addressed, facilitating comprehensive patient-centered care.
Unani diagnosis (Tashkhis) employs a systematic approach encompassing Mizaj assessment, identification of humoral imbalances, and evaluation of organ function. Modern diagnostic criteria increasingly incorporate laboratory and imaging modalities to complement traditional findings. For example, the use of liver function tests and ultrasonography in chronic hepatitis patients allows Unani practitioners to tailor interventions based on both classical and contemporary parameters. Recent advances in biomarker profiling and digital health tools are enhancing diagnostic accuracy and enabling personalized treatment planning, thereby bridging traditional knowledge with evidence-based medicine.
Unani therapeutics encompass pharmacological, dietary, regimental (Ilaj bil Tadbeer), and surgical interventions. Herbal formulations, such as Majoon-e-Dabeed-ul-Ward for hepatic disorders and Safoof-e-Muhazzil for obesity, have demonstrated efficacy in randomized controlled trials. Regimental therapies, including cupping (Hijamah), massage (Dalak), and leech therapy (Irsale Alaq), are employed for musculoskeletal and circulatory disorders. Dietary recommendations are personalized based on temperament and disease profile. Integration with conventional therapies is increasingly common, with multidisciplinary case management improving patient outcomes in chronic and complex conditions.
Recent years have witnessed the standardization of Unani medicines, development of Good Manufacturing Practices (GMP) for herbal preparations, and the application of molecular pharmacology to elucidate active constituents. Clinical trials have established the safety and efficacy of various Unani formulations in conditions such as rheumatoid arthritis, type 2 diabetes, and chronic kidney disease. Emerging therapies include nano-formulations of Unani drugs for enhanced bioavailability and the use of artificial intelligence for temperament classification. The integration of Unani with digital health records and telemedicine platforms is facilitating remote consultations and longitudinal care, especially in underserved regions.
National and international guidelines increasingly acknowledge the role of Unani as an adjunctive therapy in chronic disease management. The Central Council for Research in Unani Medicine (CCRUM) and the Ministry of AYUSH, Government of India, have published evidence-based protocols for conditions such as metabolic syndrome, liver disorders, and respiratory illnesses. Guidelines emphasize the importance of quality assurance, pharmacovigilance, and interprofessional collaboration. Physicians are encouraged to discuss Unani options with patients, ensure compatibility with existing pharmacotherapy, and monitor for potential herb-drug interactions. The World Health Organization also advocates for the integration of traditional systems, including Unani, within primary healthcare frameworks to achieve universal health coverage.
The practical advances in Unani medicine underscore its potential as a complementary and integrative approach to healthcare excellence. Scientific validation of Unani interventions, enhanced diagnostic methodologies, and robust guideline development are paving the way for its broader acceptance among healthcare professionals. Continued research, interdisciplinary collaboration, and patient-centered implementation will be pivotal in harnessing the full therapeutic potential of Unani medicine within contemporary medical practice.
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation